A clinical research study for patients who have metastatic cancer and who have never been treated with chemotherapy or immunotherapy.
Bayer HealthCare is seeking men who have metastatic cancer to participate in a research study of an investigational drug. The purpose of the ARASENS trial is to determine the safety and efficacy of a study drug at controlling prostate cancer and slowing tumor growth. The study drug being tested will be given in addition to androgen deprivation therapy (ADT) and docetaxel chemotherapy. This study is enrolling patients with metastatic prostate cancer, who are candidates for ADT and docetaxel, having recently started ADT. You will be randomly chosen for one of two groups, one of which receives the study medication with ADT and docetaxel; the other group receives a placebo (looks identical to the study medication but contains no active ingredient) with ADT and docetaxel.
To learn more about the ARASENS trial and to find out if you may be eligible, please visit: http://www.StudyProstateCancer.com or http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php(Trial Number: 17777) or www.clinicaltrials.gov(Study Identifier: NCT02799602)
Use the "clinical trials glossary" or "dictionary" for words, phrases and treatments that you may not understand